Atrial Fibrillation - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 106 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Atrial Fibrillation - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Atrial Fibrillation - Pipeline Review, H2 2014', provides an overview of the Atrial Fibrillation's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Atrial Fibrillation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atrial Fibrillation and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Atrial Fibrillation
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Atrial Fibrillation and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Atrial Fibrillation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Atrial Fibrillation pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Atrial Fibrillation
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Atrial Fibrillation pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Atrial Fibrillation Overview 9
Therapeutics Development 10
Pipeline Products for Atrial Fibrillation - Overview 10
Pipeline Products for Atrial Fibrillation - Comparative Analysis 11
Atrial Fibrillation - Therapeutics under Development by Companies 12
Atrial Fibrillation - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Atrial Fibrillation - Products under Development by Companies 17
Atrial Fibrillation - Companies Involved in Therapeutics Development 18
Bristol-Myers Squibb Company 18
AstraZeneca PLC 19
Isis Pharmaceuticals, Inc. 20
Gilead Sciences, Inc. 21
Daiichi Sankyo Company, Limited 22
Nissan Chemical Industries, Ltd. 23
Laboratoires Pierre Fabre SA 24
Cardiome Pharma Corp 25
Xention Limited 26
HUYA Bioscience International, LLC 27
Milestone Pharmaceuticals, Inc. 28
Otsuka Holdings Co., Ltd. 29
Serodus ASA 30
Nyken BV 31
Armetheon, Inc. 32
Atrial Fibrillation - Therapeutics Assessment 33
Assessment by Monotherapy Products 33
Assessment by Combination Products 34
Assessment by Target 35
Assessment by Mechanism of Action 38
Assessment by Route of Administration 41
Assessment by Molecule Type 43
Drug Profiles 45
edoxaban tosylate - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
tecarfarin - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
vernakalant hydrochloride - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
bucindolol hydrochloride - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
vernakalant hydrochloride - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
ranolazine ER - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
XEN-D0103 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
HBI-3000 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
ISIS-CRPRx - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
(ranolazine + dronedarone) - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
vanoxerine - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
F-373280 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
BMS-919373 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
XEN-D0101 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
OPC-108459 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
budiodarone - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Small Molecule to Inhibit IKACh for Atrial Fibrillation - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
MSP-2017 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
NYK-1112 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
SER-102 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
XEN-R0702 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
GsMTx-4 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
NIP-151 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Small Molecule to Block Kv1.5 for Atrial Fibrillation - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Drug For Atrial Fibrillation - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Small Molecule To Activate Heat Shock Protein 70 (Hsp70) For Post-Operative Atrial Fibrillation - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Small Molecules to Inhibit Voltage Gated Sodium Channel for Atrial Fibrillation - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Atrial Fibrillation - Recent Pipeline Updates 83
Atrial Fibrillation - Dormant Projects 95
Atrial Fibrillation - Discontinued Products 96
Atrial Fibrillation - Product Development Milestones 97
Featured News & Press Releases 97
Aug 19, 2014: First patients enrolled in study to evaluate dabigatran etexilate after PCI with stenting 97
Aug 06, 2014: Cardiome Submits Brinavess Dossier To French Authorities To Support Market Access 97
Aug 05, 2014: Cardiome Submits Brinavess Reimbursement Dossier To Belgian Authorities 98
Jul 17, 2014: Bristol-Myers Squibb and Pfizer Announce Enrollment of First Patient in Phase IV EMANATE Trial to Assess Effectiveness and Safety of Eliquis (apixaban) in Patients with NVAF Undergoing Cardioversion 98
Jul 07, 2014: Portola Pharmaceuticals Enters Into Clinical Collaboration Agreement With Daiichi Sankyo for Phase 3 Studies of Factor Xa Inhibitor Antidote, Andexanet Alfa, and Edoxaban 99
Jun 20, 2014: Boehringer Ingelheim Initiates RE-CIRCUIT Trial, Evaluating Pradaxa (dabigatran etexilate mesylate) in NVAF Patients Undergoing Ablation 100
Jun 20, 2014: New Pradaxa clinical study to explore practical management of patients with atrial fibrillation undergoing ablation 101
May 10, 2014: Gilead Announces Results from Phase 2 Study Showing Reduction in Atrial Fibrillation Burden with the Investigational Combination of Ranolazine and Low-Dose Dronedarone 102
Apr 14, 2014: Portola Pharmaceuticals Announces Publication of Phase 3 APEX Study Design and Rationale in American Heart Journal 103
Mar 31, 2014: Daiichi Sankyo Initiates Phase 3 ENSURE-AF Study, Investigating Once-Daily Edoxaban in Patients with Atrial Fibrillation Undergoing Cardioversion 104
Appendix 105
Methodology 105
Coverage 105
Secondary Research 105
Primary Research 105
Expert Panel Validation 105
Contact Us 106
Disclaimer 106

List of Tables
Number of Products under Development for Atrial Fibrillation, H2 2014 10
Number of Products under Development for Atrial Fibrillation - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 13
Comparative Analysis by Late Stage Development, H2 2014 14
Comparative Analysis by Clinical Stage Development, H2 2014 15
Comparative Analysis by Early Stage Development, H2 2014 16
Products under Development by Companies, H2 2014 17
Atrial Fibrillation - Pipeline by Bristol-Myers Squibb Company, H2 2014 18
Atrial Fibrillation - Pipeline by AstraZeneca PLC, H2 2014 19
Atrial Fibrillation - Pipeline by Isis Pharmaceuticals, Inc., H2 2014 20
Atrial Fibrillation - Pipeline by Gilead Sciences, Inc., H2 2014 21
Atrial Fibrillation - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 22
Atrial Fibrillation - Pipeline by Nissan Chemical Industries, Ltd., H2 2014 23
Atrial Fibrillation - Pipeline by Laboratoires Pierre Fabre SA, H2 2014 24
Atrial Fibrillation - Pipeline by Cardiome Pharma Corp, H2 2014 25
Atrial Fibrillation - Pipeline by Xention Limited, H2 2014 26
Atrial Fibrillation - Pipeline by HUYA Bioscience International, LLC, H2 2014 27
Atrial Fibrillation - Pipeline by Milestone Pharmaceuticals, Inc., H2 2014 28
Atrial Fibrillation - Pipeline by Otsuka Holdings Co., Ltd., H2 2014 29
Atrial Fibrillation - Pipeline by Serodus ASA, H2 2014 30
Atrial Fibrillation - Pipeline by Nyken BV, H2 2014 31
Atrial Fibrillation - Pipeline by Armetheon, Inc., H2 2014 32
Assessment by Monotherapy Products, H2 2014 33
Assessment by Combination Products, H2 2014 34
Number of Products by Stage and Target, H2 2014 37
Number of Products by Stage and Mechanism of Action, H2 2014 40
Number of Products by Stage and Route of Administration, H2 2014 42
Number of Products by Stage and Molecule Type, H2 2014 44
Atrial Fibrillation Therapeutics - Recent Pipeline Updates, H2 2014 83
Atrial Fibrillation - Dormant Projects, H2 2014 95
Atrial Fibrillation - Discontinued Products, H2 2014 96